August 16, 2025

Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.

View Full Paper

Ask AI

Bookmark

Patients with HER2-positive metastatic breast cancer had a median progression-free survival of 4.6 months.
Factors like treatment regimen significantly impacted overall survival outcomes across different breast cancer subtypes.
Observational analysis using a nationwide electronic health record-derived database examined real-world treatment effects.
Significant differences in post-treatment outcomes were observed, suggesting cross-resistance with trastuzumab deruxtecan.

Discussion

No takes yet. Share an insight, caveat, or question.

Observational analysis of post-therapy outcomes in metastatic breast cancer, indicating significant subtype differences.

Tarantino et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark